Urinary Tract Infection: Symptoms, Treatment & Red Flags

A UTI is inflammation of the urinary mucosa triggered by pathogens—usually Gram-negative rods ascending the urethra into the bladder. Host anatomy, immune competence, biofilms on devices, and prior antibiotics all shape which strain dominates and how aggressively symptoms declare themselves.

Clinicians separate lower from upper tract involvement because management intensity differs: isolated cystitis rarely needs imaging, whereas renal parenchymal infection risks bacteraemia and abscess formation. The same organism can produce either pattern depending on virulence factors, urinary drainage, and immune status.

Stratifying uncomplicated versus complicated disease drives antibiotic choice, route, duration, and need for admission. Use the table as a bedside prompt—local pathways may rename tiers but the underlying physiology is consistent.

↔On a small screen, swipe or scroll sideways to see the full table.

Classic cystitis combines irritative voiding symptoms with suprapubic discomfort. Upper-tract spread adds fever, rigors, costovertebral angle tenderness, nausea, or vomiting. Older adults may show delirium, falls, or anorexia without localising urinary complaints—maintain a low threshold to collect urine in context, but interpret pyuria cautiously.

• Lower tract: frequency, urgency, dysuria, haematuria, malodorous or cloudy urine.
• Systemic: Fever, tachycardia, hypotension, or rigors—think renal involvement or septic physiology until proven otherwise.
• Catheterised patients: new costovertebral tenderness, altered mental status, rigors, or hypotension with no alternate source.

E. coli remains the dominant uropathogen in community settings; Klebsiella, Proteus, Enterococcus, and Staphylococcus species appear more often with healthcare exposure, stones, or prior broad-spectrum therapy. Viral and fungal cystitis are uncommon except in immunosuppression.

• Modifiable: spermicide exposure, inadequate fluid intake during febrile illness, unnecessary catheter days.
• Non-modifiable: female urethral length, pregnancy, post-menopause atrophic changes, neurogenic bladder.
• Structural / functional: BPH retention, vesicoureteric reflux in children, congenital anomalies.
• Metabolic: hyperglycaemia and glucosuria support bacterial growth—align glucose checks with infection surveillance in diabetes mellitus.

Diagnosis integrates pre-test probability, urinalysis, selective culture, and imaging only when complications are suspected. Always capture specimen timing relative to any antibiotic dose already given.

Clinical assessment

Quantify dysuria, haematuria, suprapubic versus flank pain, vomiting, pregnancy status, catheter dwell time, and immunosuppression. In men, enquire about penile discharge or perineal pain that might shift the work-up toward prostatitis rather than simple cystitis.

Laboratory

• Urinalysis for nitrite, leukocyte esterase, blood, protein; microscopy helps quantify bacteriuria and WBC casts when nephritis is a concern.
• Urine culture in pregnancy, men, children, recurrent infections, hospital-acquired cases, or non-response at 48–72 h.
• Blood cultures when systemic inflammatory response, hypotension, or pyelonephritis is likely—pair with lactate per sepsis protocol.

Imaging

Not routine for first uncomplicated cystitis. Consider ultrasound or CT when stones, abscess, obstruction, or atypical organisms are suspected, or when fever persists beyond 72 h on appropriate therapy.

Clinical decision flow (bedside)

1. Stabilise—ABC, glucose check if delirium, early warning score.
2. Stratify—uncomplicated lower vs complicated vs upper vs catheter-associated.
3. Specimen—midstream clean-catch coaching; pre-catheter sample if new catheterisation planned for diagnostics.
4. Treat—match oral versus IV route to severity; align with local formulary and resistance data.
5. Reassess—document temperature curve, pain, intake/output at 48–72 h; widen diagnostics if not improving.

• Vulvovaginal candidiasis—itching dominates, dysuria is vestibular; KOH/pH clues if bedside testing available.
• Interstitial cystitis—chronic pelvic pain between voids; lacks pyuria bacteriuria pattern between flares.
• Urethritis / STI—mucopurulent discharge, sexual risk; needs different antimicrobial pathway.
• Acute retention—sudden suprapubic pain with palpable bladder—often coexists with prostatic obstruction or neurogenic causes.

Choice hinges on anatomy, pregnancy, renal function, prior culture data, and severity. Stewardship programmes (NICE NG109, IDSA) favour narrow agents for uncomplicated cystitis while reserving broader IV therapy for pyelonephritis or sepsis.

First-line oral options (uncomplicated cystitis)

• Nitrofurantoin—excellent bladder levels; avoid if eGFR below institutional threshold or if upper-tract disease suspected.
• Cephalexin or other beta-lactams when local resistance supports use and no severe allergy.
• Trimethoprim or fosfomycin (where available) per local guidance when susceptibility patterns allow.

Complicated, pregnancy, or pyelonephritis

Switch to regimens with documented renal parenchymal and blood levels—often IV beta-lactams ± aminoglycoside alternatives per protocol. Duration extends beyond three days when abscess, bacteraemia, or men is involved.

Catheter-associated infection

Treat only when urinary symptoms or systemic signs align with infection, not colonisation alone. Remove unnecessary catheters; if still required, exchange per policy alongside antibiotics. Reinforce dependent drainage and urine output monitoring.

Special populations

• Pregnancy: avoid tetracyclines and nitrofurantoin near term per local obstetric guidance; use pregnancy-safe beta-lactams.
• Renal impairment: dose-adjust agents per eGFR; avoid nephrotoxic combinations.
• Multidrug-resistant history: await cultures when clinically safe; involve microbiology early.

• Specimen quality: label bottles at bedside immediately after void; reject obvious faecal contamination where policy allows.
• Pre-antibiotic cultures: draw blood and urine before first dose when delay will not compromise unstable patients—communicate timing in handover.
• Catheter rounds: daily “continue or remove?” question reduces CAUTI incidence; document indication per CDC/NHSN expectations.
• Follow-up window: phone or clinic review at 48–72 h if symptoms persist; earlier if vomiting, inability to tolerate fluids, or single-kidney anatomy.
• Stewardship audit: capture indication on drug chart; reconcile with culture results at 48–72 h and de-escalate where possible.

Bedside monitoring checklist

• NEWS or equivalent q4–8 h while febrile.
• Strict intake/output including non-catheterised voiding logs.
• Pain and nausea scores driving antiemetics and hydration route.
• Glucose trends in diabetic patients on steroids or stress dosing.

• Pyelonephritis with bacteraemia.
• Renal abscess or perinephric collection.
• Septic shock and acute kidney injury from hypoperfusion or nephrotoxins.
• Recurrent UTI leading to antimicrobial resistance and C. difficile risk.

• Remove urinary catheters as soon as clinically safe; teach patients to question ongoing need.
• Ensure dependent drainage bags and closed systems; perform meatal hygiene per protocol.
• Post-coital voiding counselling for recurrent cystitis where evidence supports behavioural plans.
• Optimise glycaemic control and treat vulvovaginal candidiasis separately—do not mislabel as recurrent UTI.

Uncomplicated cystitis resolves rapidly with appropriate therapy; symptom relapse suggests resistant organism, stone, or incomplete treatment adherence. Pyelonephritis carries a small but important mortality in older adults and those with comorbid disease—early recognition and adequate source control determine outcomes.

Patients often equate malodorous urine with infection; nurses translate dipstick findings into plain language while avoiding false reassurance when systemic features coexist. Document decision aids used (e.g., safety-netting leaflets) and teach return precautions for new fever or flank pain.

Where acute cystitis pathways differ from broader UTI bundles, align documentation with the term your electronic record expects to maintain coding accuracy.

• Rising NEWS despite antibiotics—repeat lactate, consider imaging and broader therapy.
• New rigors after initial defervescence—blood cultures and device review.
• Reduced urine output <0.5 mL/kg/h—evaluate prerenal versus obstructive causes.

Call the medical emergency team or rapid response per local policy when vasopressors may be needed or when bedside nurses identify a time-critical change in perfusion or mentation.

Pre-treatment

Coach midstream collection after meatal cleaning; for catheter specimens use the dedicated sampling port after disinfection—never aspirate from the drainage bag for culture.

During therapy

Administer antibiotics on schedule; pair antiemetics with IV fluids when oral intake fails. Trend vitals after the first dose of any new beta-lactam for hypersensitivity monitoring.

Post-treatment evaluation

Confirm symptom resolution at 48–72 h; if not, ensure cultures are on file and escalate. When catheters are removed, observe for retention; teach signs requiring ED return.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, and matrix matching on the topic of specimen integrity, stewardship, catheter decisions, and urosepsis recognition—mirroring the Clinical Judgment Measurement Model emphasis on noticing cues and taking safe actions.